News

Public Broadcasting Service (PBS)16h
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Medscape2d
Injectable HIV Prevention Drug Gets FDA Nod
Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the US ...
FDA Approves a Twice-Yearly Shot to Prevent HIV
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
FDA approves long-lasting HIV-prevention drug
The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...
FDA approves first twice-yearly injection that prevents HIV infection
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...